Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00378066

Enrollment

Registered

2006-09-19

Start date

2006-08-31

Completion date

2008-10-31

Last updated

2013-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Brief summary

The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.

Interventions

DRUGBevacizumab

Bevacizumab, Capecitabine, Oxaliplatin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Histologically or cytologically documented colorectal adenocarcinoma * ECOG performance status of 2 or lower * Adequate bone marrow function * Adequate kidney function * Adequate liver function * Informed consent

Exclusion criteria

* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start * Known allergy to study drugs

Design outcomes

Primary

Measure	Time frame
time to progression	6 months

Secondary

Measure	Time frame
overall survival, safety, response	1 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026